U.S. Breast Imaging Market to Nearly Double by 2017
The U.S. breast imaging and mammography markets are expected to not only recover from the recession, but nearly double in the next several years.
The U.S. breast imaging and mammography markets are expected to not only recover from the recession, but nearly double in the next several years.
By 2017, the markets are expected to reach more than $1 billion, according to a new report by iData Research, a medical device and pharmaceutical market research company. The growth is expected to be driven by the replacement of older analog equipment with technologies such as digital radiography, breast-specific gamma imaging, positron emission mammography, and ultrasound equipment.
Leading the overall $2.3 billion women’s health market with sales of digital radiography equipment are Hologic and GE Healthcare, the report found. The development of breast-specific gamma imaging by Dilon Technologies and Gamma Medical, and positron emission mammography by Naviscan mean a new market for breast scans, and these technologies will experience “rapid growth,” according to Dr. Kamran Zamanian, CEO of iData.
“The majority of analog units used in 2010 are expected to be replaced by 2017,” Zamanian said in a statement.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
What if Radiology Turns Out Exactly the Way We Predict it Will?
May 19th 2025Whether it is reimbursement cuts or continued attempts to push non-radiologist image interpretation, where do we draw the line between inspired protest and misspent energy criticizing things that are doomed to fail or things we have no control over?
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
